Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study of DSP-2033 (Alvocidib) in Combination With Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin (7+3) in Patients With Acute Myeloid Leukemia

NCT03563560 is registered in ClinicalTrials.gov with Sumitomo Pharma Co., Ltd. as lead sponsor.

NCT NCT03563560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03563560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study of DSP-2033 (Alvocidib) in Combination With Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin (7+3) in Patients With Acute Myeloid Leukemia
Lead sponsor
Sumitomo Pharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 15, 2018
Completion date
March 31, 2020
Enrollment
10 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia